Murex Diagnostics UK subsidiary enters liquidation
This article was originally published in Clinica
Executive Summary
Murex Diagnostics (UK) has been forced into voluntary liquidation by a UK High Court ruling that it must post a £6 million interim security for infringement of Chiron's UK hepatitis C patent. The amount was more than the assets of the UK subsidiary of International Murex. The interim cash security, payable to Chiron and Ortho Diagnostics within seven days of the February 16th ruling, is not a final judgement on infringement damages which will be determined at a full enquiry in July (see Clinica No 680, p 16).
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.